Futura Medical Share Discussion Threads

[lbo] 24/4/2023 13:53

4 days and still no response to Glaveys question! Wake up indeed Joe!!! LOL


Glavey - 20 Apr 2023 - 23:44:08 - 18179 of 18331


Q. Why should product with no active ingredient which relies on evaporation be said to take 5-10 minutes to work?

[joestalin] 24/4/2023 13:49

6 minutes to respond? wake up!

[lbo] 24/4/2023 13:36

So none of the Eroxon studies were adequately placebo controlled? Yet Eroxon is claiming its ‘Clinically Proven’?


Medical device claims that breach CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices

‘Because the trial was not placebo-controlled’

‘had not provided adequate evidence to support the claim ‘clinically proven’ ‘concluded that the claim had not been substantiated and was misleading’



Assessment
Upheld

The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation.
CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.
There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy



Because the trial was not placebo-controlled, we considered AcceleDent had not provided adequate evidence to support the claim AcceleDent, is also clinically proven to reduce the pain and discomfort associated with braces and aligners by up to 71%. We concluded that the claim had not been substantiated and was misleading.

On that point the claim breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices, health-related products and beauty products.



Assessment
Upheld

The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation.
CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.
There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy

[lbo] 24/4/2023 13:33

If rampers make ‘sketchy’ claims some may be of the view that is a ‘snake oil’ type scam or ‘swindle’





A new threat to advertisers making sketchy health claims







companies deceptively touted

˜clinically proven’

Class members with proof of purchase are eligible to recover up to $65. Those without proof may recover up to $20.

The companies also agreed to change all references from ˜clinically proven’ and ˜science proved’ on Neuriva labeling and ancillary marketing to ‘clinically tested’ ‘science tested’ or other similar language.

Magistrate Judge Jonathan Goodman of the U.S. District Court for the Southern District of Florida granted preliminary approval April 23.

Plaintiffs attorneys will seek up to $2.9 million for fees and expenses. They will also seek incentive awards up to $2,000 each for five class representatives.




Clinically proven? Says who?

When they say clinically proven your first question should be, oh yeah, says who?

It is possible the company selling the supplement, infomercial ab gadget, or balance device did a poorly controlled ‘study’ where they had people try the product and then tell the company about their results.

While this seems logical enough, it does not constitute legitimate research.

[joestalin] 24/4/2023 13:27

He must know that the game is up - yet he persists.

[broomrigg] 24/4/2023 13:26

Well said J777J.

Set up very nicely here everyone :-)

[lbo] 24/4/2023 13:20

And wouldn’t anyone ‘loathe to give any credence’ to anything which some may have already implied is like an English AIM scam already? LOL

J777J - 23 Dec 2019 - 08:45:36 - 7043 of 9296

Clearly feels like a stitch up by Lombard who shorted after the RNS knowing they would buy back in the placing? After all it was they that underwrote it. No TR1 announcement came from them. That after something near 35% to 40% of the company's shares changed hands!!! The mysterious Butler on their payroll????? This individual appeared out of the smoke as a duo act. The obvious tactic was to spread scare stories across the various bb's.Get the price as low as possible. Lombard appear as the white knight,the great saviours,but are they in fact ruthless market manipulators?

mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141

Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says

JoeStalin - 22 Jan 2018 - 11:16:41 - 3640 of 17304

Only a clown thinks selling a few packs at all makes for a business.


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders

[j777j] 24/4/2023 13:15

Classis bear trap

Product is flying off the shelves,Lombard merely providing liquidity.

Multiple launches to hit the RNS's soon

USA approval any week now.


See you at 125p

[broomrigg] 24/4/2023 12:53

Page refreshed at 1252 hrs

Last sale of Eroxon 22 seconds ago.

LOVE IT they are being snapped up like hot cakes peeps :-)

[broomrigg] 24/4/2023 12:51

Lunchtime Eroxon sales check on boots.com at 1249 hrs......

Last purchase was 9 seconds ago

Say no more Rodney! :-)

[petroc] 24/4/2023 12:19

LiarBO buried his own nonsense post just then, unsurprisingly. He stated 'If Flexiseq is a ‘Russian gangster scam’ then the multi-ID ramper is implying Med3000/Eroxon is an AIM English gangster scam? ROFLMAO:'

Obviously he didn't post any links to support his outrageous claim, because he knows it's just childish nonsense, the like of which you could hear in any school playground. 'You're a gangster scam! Nanananana!' 'I know you are, what am I?'

ROFLMAO indeed.

[lbo] 24/4/2023 11:30

https://regencyresearch.co.uk/weekly-briefing/weekly-briefing-friday-21st-april/REGENCY VIEW:The launch of Eroxon is a pivotal moment, but before investors get too excited it's important to keep in mind Futura's flaccid financials...Futura has been burning through cash for several years and has a relatively small 'cash runway' based on its current free cash flow.Whilst cashflow should significantly improve as Eroxon is rolled out, investors are likely to be diluted when Futura inevitably recapitalise.

[lbo] 24/4/2023 11:23

LOL

A stopped clock is more accurate!

Broomrigg - 07 Jan 2023 - 06:11:55 - 15544 of 18317
FUM to hit 60p next week?

Broomrigg - 15 Dec 2022 - 11:05:32 - 14865 of 18318
If we break out above 60p this month (this week?!) it will be VERY interesting to learn what Zak Mir's new target will be.

[lbo] 24/4/2023 11:17

Oh no the connnected multi-ID rampers are out beating their pumpty dumpty drums all over the Internet yet again! Didn’t Zak say over 60p before end December 2022? LOL

Didn’t Zaks podcast also have Albert on saying that Med3000/Eroxon was a ‘new drug’ when actually its only a medical device?

andyr42 - 23 Mar 2021 - 15:03:15 - 9033 of 17363

whats the gut feel of you telegram group. Care to share pls?

Billthebank - 23 Mar 2021 - 14:06:06 - 9029 of 17363

TBH no I do not normally get it right but I did today thanks to a couple of people in the telegram group.

Albert Arthur - 08 Dec 2021 - 14:43:19 - 10140 of 17333
I did a couple of Sunday roast, I mentioned FUM



Zak Mir is joined by Sunday Roast regulars Albert Arthur



Alberts week 1m 48s on Futura Medical (FUM) new drug 2m 34s



Albert Arthur8 Dec '21 - 11:16 - 10125 of 16732

Bot streams to Twitter and Telegram

Albert Arthur - 21 Mar 2021 - 13:56:12 - 8701 of 17333
I spoke with Zak about FUM Friday.








Broomrigg - 14 Dec 2022 - 12:41:29 - 14800 of 16193
Today's Trader's Cafe with Zak Mir: Bulletin Board Heroes (on Vox markets)......

(Listen from 6m 5s)

He's looking for 60p by the end of the month (note: this is just on chart analysis and does not take into account potential news flow re. revenues next year which will leave 60p in the dust).

[lbo] 24/4/2023 11:12

Just like Pet500 and CSD500 could have been something but failed to sell long term even though they had more USPs and enforceable patents! Yet Reckitt still have similar products to those Futura failed products on the market! And they and GSk both walked away from MED!

If It does get De Novo medical device registration and there actually is a real market for drug free male arousal gels for psychogenic ED. It wont take long for Reckitt or competitors if they are inclined to launch a similar alcohol, water, glycol and Carbopol arousal gel product for men via the 510k pathway!

A De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device

The average length of time for clearance under the traditional 510(k) pathway is 177 days,



A company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially



Here's a startling fact: between 80% and 90% of new product launches fail, according to multiple studies including Harvard Business Review. Each year, more than 30,000 new products hit the market, from companies large and small, and year after year, history is littered with dead carcasses



Research at the Ehrenberg-Bass Institute shows new product launches can be a risky undertaking for brand owners. Investigating 83,719 new product introductions over an eight-year period, the research finds around one in four new products failed to survive one year after launch. This failure rate increased to around 40% two years after launch.



Why Most Product Launches

[broomrigg] 24/4/2023 11:11

From last Thursday, not sure if it got posted on here yet......Zak Mir talking 70p soon and that of course is just from chart analysis (if you believe in all that stuff) and will be blown away by FDA approval/other expected positive RNS updates.

(listen from 6mins 40secs)

[lbo] 24/4/2023 11:07

Morning Folks! Reality sales check! A one year hit wonder placebo gel isn’t the same as the ‘work hard’ that Futura openly admitted in the results that is needed to try turn it ‘into a long term, profitable and trusted brand."

Flexiseq had ‘sales of more than 3 million units since its U.K. launch’ in Year 1. Then a few years later struggled to pay the interest on its loan!




The secured loan of US$15 million, which matures on June 25, 2018, will bear interest at 12% per annum plus other additional consideration. The interest rate will decrease to 10% if Pro Bono Bio meets certain equity-fundraising targets. The loan is secured by a charge over the assets of Pro Bono Bio and its affiliates which includes but is not limited to Flexiseq, an innovative topical pain product that has sales of more than 3 million units since its U.K. launch last year.

In 2017, PBB was on the verge of bankruptcy, because it could not pay interest on the loan of 15 million pounds, taken in 2015 by the Canadian Knight Therapeutics.

[haroldthegreat] 24/4/2023 11:01

That is why when you purchase viagra the pharmacy asks a load of questions !

[broomrigg] 24/4/2023 10:58

Morning folks!

Sales check on the boots.com website @ 1057hrs

Last sale of Eroxon 18 seconds ago.

Nice :-)

[haroldthegreat] 24/4/2023 10:58

The advantage of this is that there are no interactions with other medications . Taking a viagra with certain other medications could be fatal .

[haroldthegreat] 24/4/2023 10:54

Waste of time posting boots on line sales it is obvious they are selling in shop and on line . There is a demand for an efficient safe product . Anyone can sell a new product once to.anyone its the repeat sales that count . Having said that this problem affects a large percentage of males so the initial sales could be massive . Especially If there is a massive response !